Share Price Movement and Market Context
On 24 Nov 2025, Shree Ganesh Biotech India’s stock price settled at Rs.0.64, establishing both a fresh 52-week and all-time low. This price level is notably below its 52-week high of Rs.1.19, reflecting a substantial contraction in market value over the past year. Despite the stock’s decline, the broader market has demonstrated strength; the Sensex opened 88.12 points higher and was trading at 85,379.45, a 0.17% gain. The Sensex is also approaching its own 52-week high of 85,801.70, supported by bullish moving averages and a three-week consecutive rise, with mega-cap stocks leading the advance.
Shree Ganesh Biotech India’s share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning indicates sustained downward momentum relative to its recent trading history and suggests that the stock has not found short-term support levels.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Financial Performance and Profitability Metrics
Over the last year, Shree Ganesh Biotech India’s stock has recorded a return of -37.50%, contrasting with the Sensex’s positive return of 7.90% over the same period. The company’s financial results for the nine months ending September 2025 reveal a contraction in net sales to Rs.5.16 crores, representing a decline of 44.64% compared to the previous period. Correspondingly, the profit after tax (PAT) stood at a loss of Rs.0.61 crores, also reflecting a 44.64% reduction.
The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) have been negative, which adds to the concerns regarding its earnings capacity. The average EBIT to interest ratio is 0.91, indicating limited ability to cover interest expenses from operating earnings. Return on equity (ROE) has averaged 2.62%, signalling modest profitability relative to shareholders’ funds.
Additionally, the debtors turnover ratio for the half-year period is reported at 0.00 times, suggesting challenges in receivables management or collection efficiency. These financial indicators collectively point to a constrained operational and financial position for the company.
Shareholding and Market Risk Considerations
Shree Ganesh Biotech India’s shareholding structure is dominated by non-institutional investors, which may influence liquidity and trading dynamics. The stock is considered risky relative to its historical valuation levels, reflecting the volatility and uncertainty surrounding its financial health and market performance.
Holding Shree Ganesh Biotech India from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Sector and Industry Context
Operating within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Biotech India faces a competitive environment where innovation, regulatory compliance, and financial stability are critical. The sector itself has shown resilience, with many companies benefiting from sustained demand and favourable market conditions. However, Shree Ganesh Biotech India’s current financial metrics and share price trajectory suggest it has not aligned with these broader sector trends.
Summary of Key Price and Performance Data
To summarise, the stock’s 52-week low of Rs.0.64 is a significant milestone reflecting the challenges faced by Shree Ganesh Biotech India. The stock’s performance over the past year, with a negative return of 37.50%, contrasts sharply with the Sensex’s positive trajectory. The company’s financial results, including a 44.64% decline in net sales and a corresponding loss in PAT, alongside negative EBITDA and weak coverage of interest expenses, highlight the pressures on its earnings and cash flow generation.
Trading below all major moving averages, the stock’s technical indicators reinforce the downward trend. Meanwhile, the broader market environment remains positive, with the Sensex near its 52-week high and supported by strong mega-cap performance.
Investors and market participants observing Shree Ganesh Biotech India will note these developments as part of the company’s ongoing market narrative.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
